( Leading cardiologist Naresh Trehan Wedn...)Trehan Quits Escorts, Plans to Join Apollo,Health
Navigation Links
Trehan Quits Escorts, Plans to Join Apollo
Leading cardiologist Naresh Trehan Wednesday resigned from the post of executive director of Escorts Hospital and will completely disengage himself from the hospital from June 1.
'"/>
Related medicine news :
1. Naresh Trehan Removed from Escorts Hospital
2. Naresh Trehan Reinstated as Chief of Escorts After Weeklong Row
3. Women find difficulty in calling it Quits
4. UK Nurses Complain of Stress, One Quits After Screaming at Heart Attack Patient
5. Sharad Pawar admitted to Escorts, condition stable
6. Wockhardt Group Plans Hospital In Delhi By End-2007
7. Alberta’s New Reform Plans In Health Care Secto
8. Blue Cross Signs Up 110,000 Minnesotans For Part D Medicare Plans
9. Little Clinic LLC Plans Super Medical Clinics in Publix Super Markets
10. Medicare Drug Plans Are Onerous and Restrictive
11. Rajasthan Plans To Run Christian Institutions
Post Your Comments:
Breaking Medicine News(10 mins):Health News:Help Young Cancer Patients Enjoy Christmas This Season 2Health News:Thomson Reuters Releases Micromedex 2.0 2Health News:Thomson Reuters Releases Micromedex 2.0 3Health News:Drummond Group Awarded DOE Funds for Texas Wind Integration Project 2Health News:Drummond Group Awarded DOE Funds for Texas Wind Integration Project 3Health News:Drummond Group Awarded DOE Funds for Texas Wind Integration Project 4Health News:Online Medical Supply Superstore Adds Cure Catheters to Product Mix 2Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 2Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 3Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 4Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 5
[0] Help Young Cancer Patients Enjoy Christmas This Season[0] Thomson Reuters Releases Micromedex 2.0[0] Drummond Group Awarded DOE Funds for Texas Wind Integration Project [1] Online Medical Supply Superstore Adds Cure Catheters to Product Mix [0] Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data
Other Medicine News:Health News:MR spectroscopy identifies breast cancer, reduces biopsies 2Health News:ISTO Technologies Receives 510(k) Clearance for a Novel Bone Graft Substitute and Bone Graft Extender 2Health News:September/October 2007 Annals of Family Medicine tip sheet 2Health News:September/October 2007 Annals of Family Medicine tip sheet 3Health News:September/October 2007 Annals of Family Medicine tip sheet 4Health News:September/October 2007 Annals of Family Medicine tip sheet 5Health News:September/October 2007 Annals of Family Medicine tip sheet 6Health News:September/October 2007 Annals of Family Medicine tip sheet 7Health News:Older blacks and Latinos still lag whites in controlling diabetes 2Health News:Older blacks and Latinos still lag whites in controlling diabetes 3Health News:Older blacks and Latinos still lag whites in controlling diabetes 4Health News:Older blacks and Latinos still lag whites in controlling diabetes 5
MR spectroscopy identifies breast cancer, reduces biopsiesPelosi: 'Mr. President - Drop the Partisan Rhetoric, Put Down the Veto Pen'ISTO Technologies Receives 510(k) Clearance for a Novel Bone Graft Substitute and Bone Graft ExtenderSeptember/October 2007 Annals of Family Medicine tip sheetOlder blacks and Latinos still lag whites in controlling diabetesNIH scientists describe ways to better assess benefits of influenza vaccine in the elderly
Breaking Medicine Technology:Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 2Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 3Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 3The first men and women from the Canary Islands were Berbers 10464 1The first men and women from the Canary Islands were Berbers 10464 2The first men and women from the Canary Islands were Berbers 10464 3El Paso County serves as a model for obesity prevention according to UT School of Public Health study 10459 1El Paso County serves as a model for obesity prevention according to UT School of Public Health study 10459 2El Paso County serves as a model for obesity prevention according to UT School of Public Health study 10459 3Seattle Public Schools Get Free 26amp 3B 238220 3BHelmets 4 Safety 26amp 3B 238221 3B 59913 1Seattle Public Schools Get Free 26amp 3B 238220 3BHelmets 4 Safety 26amp 3B 238221 3B 59913 2Seattle Public Schools Get Free 26amp 3B 238220 3BHelmets 4 Safety 26amp 3B 238221 3B 59913 3Seattle Public Schools Get Free 26amp 3B 238220 3BHelmets 4 Safety 26amp 3B 238221 3B 59913 4
[0] Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial[0] Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment[0] Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects
Other Medicine Technology:Nearly 1 in 10 Americans Has A Relative With Kidney Failure 2Chemokine Therapeutics Announces Preliminary Results of CTCE-9908,Phase Ib/II Clinical Trial in Late Stage Cancer Patients 2Chemokine Therapeutics Announces Preliminary Results of CTCE-9908,Phase Ib/II Clinical Trial in Late Stage Cancer Patients 3Chemokine Therapeutics Announces Preliminary Results of CTCE-9908,Phase Ib/II Clinical Trial in Late Stage Cancer Patients 4Chemokine Therapeutics Announces Preliminary Results of CTCE-9908,Phase Ib/II Clinical Trial in Late Stage Cancer Patients 5
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |